Navigation Links
Biosimilars of Rituxan, MabThera, Herceptin and Erbitux will Erode $8.2 Billion in U.S. and European Sales in 2018
Date:9/15/2009

WALTHAM, Mass., Sept. 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that U.S. and European (France, Germany, Italy, Spain and U.K.) sales of Roche/Biogen Idec's Rituxan/MabThera, Bristol-Myers Squibb/Merck's Erbitux and Roche's Herceptin will peak at almost $16 billion in 2014, before falling to roughly $10 billion in 2018. Biosimilars of these three branded agents are forecasted to erode $8.2 billion in U.S. and European sales in 2018 but they are expected to capture only $4.6 billion in sales due to their lower prices.

"Biosimilars of the five brands covered in this report (Rituxan/MabThera, Erbitux, Herceptin, Amgen's Neupogen and Neulasta) will erode $34.3 billion in brand sales during our 2008-2018 forecast period across the U.S. and Europe and save health care systems $17.3 billion in the process," stated Michael Malecki, Ph.D., analyst and product manager at Decision Resources.

The new special report entitled Biosimilars: G-CSFs and Monoclonal Antibodies in Oncology also finds that oncologists are expected to demand clinical data for biosimilars demonstrating equivalence in multiple subpopulations. That is, although a biosimilar may be labeled for use in multiple subpopulations, oncologists will not feel comfortable prescribing a biosimilar without clinical validation.

Over time, oncologists are expected to become more comfortable using biosimilars in subpopulations and/or indications for which the reference product is approved but not clinically validated. In order to slow the growth of physician comfort in this regard, makers of branded biologics should emphasize the proven efficacy records of their agents and the importance of using a fully validated therapy for patients with life-threatening disease.

"Although surveyed oncologists are the most aggressive in treating cancers, they are hesitant to prescribe a biosimilar if it has not been clinically studied for the indication they are treating, even if the biosimilar is labeled for the indication in question," added Dr. Malecki.

Decision Resources expands the scope and analysis of its biosimilars product line to include oncology, immune and infectious disease and endocrinology/nephrology in three separate reports. The new report series covers 22 key biologic brands from eight biologic classes and include surveys of 456 U.S. and European physicians and 41 managed care organization pharmacy and medical directors.

Webinar

Members of the media are welcome to attend our upcoming webinar entitled Biosimilars in Oncology: A Potential $25 Billion in Lost Revenue. This webinar will be held on Thursday, October 8, 2009 at 10 a.m. U.S. Eastern Time. For more information, please contact Gisselle Morales at 781-296-2691 or by email at gmorales@dresources.com.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


    For more information, contact:

    Decision Resources                     Decision Resources, Inc.
    Christopher Comfort                    Elizabeth Marshall
    781-296-2597                           781-296-2563
    ccomfort@dresources.com                emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GPhA Statement on Introduction of H.R. 1548, The Pathway for Biosimilars Act
2. Decision Resources White Paper Discusses Increasing Reality of Biosimilars and their Impact on Biologics Market
3. Broad Stakeholder Coalition Concludes that the Pathway for Biosimilars Act Fails to Ensure Timely Access to Safe, Affordable Biogeneric Medicines for Patients
4. Routine Testing Would Improve Herceptin Use in Breast Cancer
5. Mathematical modeling predicts response to Herceptin
6. If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer
7. Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
8. Herceptin helps women with multiple chromosomes containing HER2 gene, study finds
9. Erbitux May Help Some With Colorectal Cancer
10. Use of Avastin and Erbitux in the Adjuvant Setting and Launches of Emerging Agents Will Drive the Colorectal Cancer Drug Market to $7.8 Billion in 2017
11. Erbitux Works Well for Two-Thirds of Colon Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
Breaking Medicine Technology: